Edition:
United Kingdom

Sartorius Stedim Biotech SA (STDM.PA)

STDM.PA on Paris Stock Exchange

60.02EUR
15 Dec 2017
Change (% chg)

€-0.51 (-0.84%)
Prev Close
€60.53
Open
€60.38
Day's High
€60.39
Day's Low
€59.88
Volume
52,476
Avg. Vol
49,503
52-wk High
€72.74
52-wk Low
€50.13

Latest Key Developments (Source: Significant Developments)

Sartorius Stedim Biotech 9-month EBITDA up at ‍​216.2 million euros
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::9 MONTHS SALES REVENUE EUR 806.5 ‍​ MILLION VERSUS EUR 785.1 MILLION YEAR AGO.9 MONTHS EBITDA EUR ‍​216.2 MILLION VERSUS EUR 214.1 MILLION YEAR AGO.9 MONTHS NET PROFIT EUR 132.1‍​ MILLION VERSUS EUR 131.3 MILLION YEAR AGO.‍FULL-YEAR 2017 GUIDANCE ADJUSTED, MID-TERM OUTLOOK CONFIRMED​.‍FOR 2017 NOW EXPECTS THAT SALES REVENUE GROWTH WILL REACH APPROX. 4% IN CONSTANT CURRENCIES ​.‍FOR 2017 UNDERLYING EBITDA MARGIN WILL BE APPROX. AT PRIOR-YEAR LEVEL OF 27.5%​.FOR 2017 ‍CAPITAL EXPENDITURES ARE EXPECTED TO BE AT UPPER END OF BANDWIDTH OF AROUND 10% TO 13% OF SALES.​.  Full Article

Sartorius Stedim Biotech cuts 2017 outlook
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::REPORTED ON MONDAY 9-MONTH SALES REVENUE EUR 806 MLN, UP 3.3 PCT IN CONSTANT CURRENCIES.9-MONTH UNDERLYING EBITDA MARGIN AT 26.8 PCT VS 27.3 PCT YEAR AGO.IN 2017 SEES INCREASE OF SALES REVENUE IN CONSTANT CURRENCIES BY ABOUT 4 PCT (VS PREVIOUS GUIDANCE FROM ABOUT 8 PCT TO 12 PCT) .IN 2017 SEES UNDERLYING EBITDA MARGIN IN CONSTANT CURRENCIES AT ABOUT THE PRIOR-YEAR LEVEL OF 27.5 PCT (VS PREVIOUS GUIDANCE ABOUT +0.5 PCT POINTS VS FY 2016).CONFIRMS MID-TERM TARGETS.  Full Article

Sartorius Stedim Biotech H1 revenue up 20.6 pct to 508.8 million euros
Monday, 25 Jul 2016 

Sartorius Stedim Biotech SA : H1 revenue 508.8 million euros ($558.41 million) versus 422.0 million euros year ago . H1 net profit 83.5 million euros versus 62.9 million euros year ago . H1 EBITDA 136.4 million euros versus 106.5 million euros year ago . Outlook for 2016 raised . Sales revenues are now expected to increase by about 17 pct to 20 pct in constant currencies .Underlying EBITDA margin is projected to rise about 1.5 percentage points in constant currencies.  Full Article

Sartorius Stedim Biotech Acquires U.S. start up Ksep systems
Wednesday, 6 Jul 2016 

Sartorius Stedim Biotech : Acquires U.S. start up Ksep systems . Transaction values Ksep at around $28 million and will be closed by end of July 2016 .Ksep holdings, inc. Expected to achieve significant double-digit growth and to generate around $7 million sales revenues and a strong double-digit EBITDA margin in 2016.  Full Article

Sartorius Stedim Biotech proposes FY 2015 dividend
Thursday, 25 Feb 2016 

Sartorius Stedim Biotech SA:To submit proposal to pay a dividend of 2.00 euros per share for FY 2015, up from 1.30 euros a year earlier.  Full Article

Sartorius Stedim Biotech gives guidance for 2016 and 2020
Monday, 1 Feb 2016 

Sartorius Stedim Biotech SA:Forecasts 2016 sales revenue will increase 12 pct to 16 pct and underlying EBITDA margin will rise approx. one percentage point​.‍Management anticipates that in 2020 sales revenue will reach about 1.5 to 1.6 billion euros and underlying EBITDA margin will attain about 29 to 30 pct.  Full Article

BRIEF-Sartorius Stedim Biotech 9-month EBITDA up at ‍​216.2 million euros

* 9 MONTHS SALES REVENUE EUR 806.5 ‍​ MILLION VERSUS EUR 785.1 MILLION YEAR AGO